治疗抗治疗单极性抑郁症的普拉米佩克索尔增量不响应阿里皮普拉增量:一项观察性研究
Antonio Tundo1, Sophia Betro'1, Rocco de Filippis1
1Institute of Psychopathology, Clinical section, Rome.
Journal of clinical psychopharmacology
|March 31, 2025
概括
普拉米佩克索尔增强剂 (PA) 对治疗耐药性抑郁症 (TRD) 患者有希望,这些患者对阿里皮普拉尔增强剂 (AA) 没有反应. 以前接受AA治疗的患者和未接受AA治疗的患者之间,有效性和安全性是可比的.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐治疗抑郁症 (TRD) 影响了许多患者,目前的增强策略的成功程度有限.
- 阿里皮普拉增强剂 (AA) 对一些TRD患者有效,但超过50%的患者没有反应.
- 研究替代增强策略对于改善TRD治疗结果至关重要.
研究的目的:
- 评估普拉米醇增强剂 (PA) 在单极TRD患者中的有效性和安全性.
- 为了比较以前未接受AA的患者和以前没有接受AA的患者的PA结果.
- 评估PA的短期和长期疗效和安全性概况.
主要方法:
- 一项涉及81名单极TRD患者的观察性研究.
- 患者被分为两组:那些以前未能接受AA治疗的人 (FAA) 和那些以前没有接受AA治疗的人 (UAA).
- 短期 (24周) 和长期 (24个月) 疗效 (缓解,反应,改善,功能) 和安全结果进行了比较.
主要成果:
- 在FAA和UAA组之间没有观察到明显的差异,在24周内缓解,反应,改善或功能方面没有明显差异.
- 在24个月后的长期复发率也在两组之间相似.
- 两组都表现出类似的安全结果,包括短期和长期的可接受性,耐受性和自杀倾向.
结论:
- 非标签的普拉米醇增强剂 (PA) 似乎是单极TRD患者的有希望的治疗选择,包括那些没有对阿里皮普拉醇增强剂 (AA) 反应的人.
- 这些发现表明,PA对于有AA失败史的患者来说是一个可行的替代方案.
- 由于研究的局限性,需要对更大的样本大小和受控设计进行进一步的研究来证实这些初步发现.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
170
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
170
Parkinson's Disease: Treatment
162
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
162
Psychosis: Goals of Pharmacotherapy
98
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
98
Mania and Antimanic Drugs: Overview
106
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
106
Psychosis and Antipsychotic Drugs: Overview
159
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
159
Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32


